Corvus Pharmaceuticals, Inc. (CRVS)
CRVSNASDAQ-GMBiotechnology: Pharmaceutical Preparations
$10.64
-0.0700 (-0.65%) today
At the close, Nov 13, 4:00 PM ET. Pre-market $12.00 +12.78%
- Market cap
- $1.01bn
- P/E
- –
- EPS, last 4 quarters
- $-0.7100
- Dividend yield
- –
- Day range
- –
- 52-week range
- $6.39 to $26.95
- Average volume
- –
- Previous close
- $10.71
Analysts
4 coveringBuy4 buy, 0 hold, 0 sell
Targets a year out average $28.75, +170.2% from here
Earnings
next estimate $-0.2300Next report
Dec 2025
-7.1%
Mar 2026
-7.1%
Jun 2026
-11.8%
Sep 2026
-4.8%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$12.22m | -$14.88m | -$19.30m | -$21.36m |
| Net income | -$12.32m | -$13.69m | -$17.96m | -$20.34m |
News
8 latest- Corvus (CRVS) Q3 2026 Earnings Call TranscriptThe Motley Fool · Nov 6, 2026
- Corvus Pharmaceuticals Reports Third Quarter 2026 Financial ResultsFintel · Nov 6, 2026
- What Corvus Pharmaceuticals (CRVS) Said on Its Q3 Earnings CallMarketBeat · Nov 5, 2026
- Noteworthy Thursday Option Activity: NOW, WOLF, CRVSBNK Invest · Oct 15, 2026
- Corvus Begins Patient Enrollment In Phase 1b Soquelitinib Trial For Hidradenitis Suppurativa RTTNews · Oct 1, 2026
- Corvus Pharmaceuticals (CRVS) Q2 2026 Earnings Call TranscriptThe Motley Fool · Aug 14, 2026
- Corvus Pharmaceuticals Q2 Earnings Call HighlightsMarketBeat · Aug 6, 2026
- Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy?The Motley Fool · Jun 23, 2026
The company
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of immune diseases and cancer. The Company's lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Soquelitinib is being evaluated in a registrational Phase 3 clinical trial for relapsed/refractory peripheral T cell lymphoma (PTCL), a Phase 2 clinical trial for the treatment of atopic dermatitis, and a Phase 1b clinical trial for hidradenitis suppurativa. Its other clinical-stage candidates are being developed for a variety of cancer indications.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- corvuspharma.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.